MINODRONIC ACID

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C9H12N2O7P2
Molecular Weight	322.1483
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(CC1=CN=C2C=CC=CN12)(P(O)(O)=O)P(O)(O)=O

InChI

InChIKey=VMMKGHQPQIEGSQ-UHFFFAOYSA-N

InChI=1S/C9H12N2O7P2/c12-9(19(13,14)15,20(16,17)18)5-7-6-10-8-3-1-2-4-11(7)8/h1-4,6,12H,5H2,(H2,13,14,15)(H2,16,17,18)

HIDE SMILES / InChI

Molecular Formula	C9H12N2O7P2
Molecular Weight	322.1483
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://dx.doi.org/10.1016%2Fs0065-7743%2810%2945028-9
Curator's Comment: description was created based on several sources, including https://www.astellas.com/en/corporate/news/pdf/110915_en_2.pdf | https://www.ncbi.nlm.nih.gov/pubmed/21110804

Minodronic acid (RECALBON®, Bonoteo®), a third-generation bisphosphonate, was approved in Japan for the oral treatment of osteoporosis. This drug increases the bone mineral density and the strength by inhibiting osteoclastic bone resorption. Nitrogen-containing bisphosphonates, such as minodronic acid (RECALBON®, Bonoteo®) induce osteoclast apoptosis by inhibiting farnesyl pyrophosphate synthase (FPPS), a key enzyme in the mevalonate pathway. Inhibition of FPPS in osteoclasts prevents the biosynthesis of isoprenoid lipids that are required for the prenylation of small GTPase signaling proteins necessary for osteoclast function. Similarly, nitrogen-containing bisphosphonates have been shown to inhibit farnesyl pyrophosphate/geranyl pyrophosphate synthase activity.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Geranylgeranyl pyrophosphate synthetase 18 Target ID: CHEMBL4769 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21110804	Inhibitor 8504	0.67 µM [IC50]
Farnesyl diphosphate synthase 28 Target ID: CHEMBL1782 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21110804	Inhibitor 8504	0.003 µM [IC50]
P2X2/P2X3 receptor 2 Target ID: CHEMBL3137277 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28243795	Antagonist 2849	62.7 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Osteoporosis 101 Sources: https://www.astellas.com/en/corporate/news/pdf/090121_eg.pdf	Primary		Approved 8583	BONOTEO Approved Use The drug was developed for the treatment of osteoporosis. Launch Date 2009

C_max

Value	Dose	Analyte	Population
0.3895 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/800126_3999026F1026_1_017_1F.pdf#page=46	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.1913 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/800126_3999026F1026_1_017_1F.pdf#page=46	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.405 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/800126_3999026F1026_1_017_1F.pdf#page=46	4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.638 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/800126_3999026F1026_1_017_1F.pdf#page=46	4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.216 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/800126_3999026F1026_1_017_1F.pdf#page=46	4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
0.072 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900002/80012600_22100AMX00391_K100_1.pdf#page=26	0.1 mg single, oral dose: 0.1 mg route of administration: Oral experiment type: SINGLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.017 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900002/80012600_22100AMX00391_K100_1.pdf#page=26	0.2 mg single, oral dose: 0.2 mg route of administration: Oral experiment type: SINGLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.119 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900002/80012600_22100AMX00391_K100_1.pdf#page=26	0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.189 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900002/80012600_22100AMX00391_K100_1.pdf#page=26	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.726 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900002/80012600_22100AMX00391_K100_1.pdf#page=26	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.665 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900002/80012600_22100AMX00391_K100_1.pdf#page=26	4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2.431 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900002/80012600_22100AMX00391_K100_1.pdf#page=26	8 mg single, oral dose: 8 mg route of administration: Oral experiment type: SINGLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.874 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900002/80012600_22100AMX00391_K100_1.pdf#page=28	4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2.85 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900002/80012600_22100AMX00391_K100_1.pdf#page=28	8 mg single, oral dose: 8 mg route of administration: Oral experiment type: SINGLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2.333 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900002/80012600_22100AMX00391_K100_1.pdf#page=28	12 mg single, oral dose: 12 mg route of administration: Oral experiment type: SINGLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.3134 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/800126_3999026F1026_1_017_1F.pdf#page=44	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.2564 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/800126_3999026F1026_1_017_1F.pdf#page=44	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
0.5555 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/800126_3999026F1026_1_017_1F.pdf#page=44	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.6512 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/800126_3999026F1026_1_017_1F.pdf#page=44	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
0.676 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/800126_3999026F1026_1_017_1F.pdf#page=45	2 mg 1 times / day multiple, oral dose: 2 mg route of administration: Oral experiment type: MULTIPLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.93 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/800126_3999026F1026_1_017_1F.pdf#page=45	2 mg 1 times / day multiple, oral dose: 2 mg route of administration: Oral experiment type: MULTIPLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
1.549 ng × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/800126_3999026F1026_1_017_1F.pdf#page=46	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.445 ng × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/800126_3999026F1026_1_017_1F.pdf#page=46	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4.12 ng × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/800126_3999026F1026_1_017_1F.pdf#page=46	4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.41 ng × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/800126_3999026F1026_1_017_1F.pdf#page=46	4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.7 ng × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/800126_3999026F1026_1_017_1F.pdf#page=46	4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
0.04 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900002/80012600_22100AMX00391_K100_1.pdf#page=26	0.1 mg single, oral dose: 0.1 mg route of administration: Oral experiment type: SINGLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.01 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900002/80012600_22100AMX00391_K100_1.pdf#page=26	0.2 mg single, oral dose: 0.2 mg route of administration: Oral experiment type: SINGLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.19 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900002/80012600_22100AMX00391_K100_1.pdf#page=26	0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.37 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900002/80012600_22100AMX00391_K100_1.pdf#page=26	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2.15 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900002/80012600_22100AMX00391_K100_1.pdf#page=26	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2.26 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900002/80012600_22100AMX00391_K100_1.pdf#page=26	4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
9.28 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900002/80012600_22100AMX00391_K100_1.pdf#page=26	8 mg single, oral dose: 8 mg route of administration: Oral experiment type: SINGLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3.52 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900002/80012600_22100AMX00391_K100_1.pdf#page=28	4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
10.98 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900002/80012600_22100AMX00391_K100_1.pdf#page=28	8 mg single, oral dose: 8 mg route of administration: Oral experiment type: SINGLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
10.16 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900002/80012600_22100AMX00391_K100_1.pdf#page=28	12 mg single, oral dose: 12 mg route of administration: Oral experiment type: SINGLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.325 ng × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/800126_3999026F1026_1_017_1F.pdf#page=44	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.074 ng × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/800126_3999026F1026_1_017_1F.pdf#page=44	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
2.814 ng × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/800126_3999026F1026_1_017_1F.pdf#page=44	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3.051 ng × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/800126_3999026F1026_1_017_1F.pdf#page=44	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
1.92 ng × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/800126_3999026F1026_1_017_1F.pdf#page=45	2 mg 1 times / day multiple, oral dose: 2 mg route of administration: Oral experiment type: MULTIPLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3.24 ng × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/800126_3999026F1026_1_017_1F.pdf#page=45	2 mg 1 times / day multiple, oral dose: 2 mg route of administration: Oral experiment type: MULTIPLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
9.7 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/800126_3999026F1026_1_017_1F.pdf#page=46	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
6.6 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/800126_3999026F1026_1_017_1F.pdf#page=46	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.3 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/800126_3999026F1026_1_017_1F.pdf#page=46	4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.4 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/800126_3999026F1026_1_017_1F.pdf#page=46	4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.7 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/800126_3999026F1026_1_017_1F.pdf#page=46	4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
2.3 h OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900002/80012600_22100AMX00391_K100_1.pdf#page=28	4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4.7 h OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900002/80012600_22100AMX00391_K100_1.pdf#page=28	8 mg single, oral dose: 8 mg route of administration: Oral experiment type: SINGLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4.4 h OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900002/80012600_22100AMX00391_K100_1.pdf#page=28	12 mg single, oral dose: 12 mg route of administration: Oral experiment type: SINGLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
8.2 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/800126_3999026F1026_1_017_1F.pdf#page=44	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
11.5 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/800126_3999026F1026_1_017_1F.pdf#page=44	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
9.7 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/800126_3999026F1026_1_017_1F.pdf#page=44	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
9.9 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/800126_3999026F1026_1_017_1F.pdf#page=44	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	MINODRONIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
38.1% OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900002/80012600_22100AMX00391_A101_1.pdf#page=19			MINODRONIC ACID plasma	Homo sapiens

Doses

Dose	Population	Adverse events
56 mg single, oral Higher than recommended Dose: 56 mg Route: oral Route: single Dose: 56 mg Sources: https://pubmed.ncbi.nlm.nih.gov/23774552/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/23774552/	Other AEs: Acute kidney injury... Other AEs: Acute kidney injury Sources: https://pubmed.ncbi.nlm.nih.gov/23774552/
4 mg single, oral Highest studied dose Dose: 4 mg Route: oral Route: single Dose: 4 mg Sources: https://pubmed.ncbi.nlm.nih.gov/25748293/	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: https://pubmed.ncbi.nlm.nih.gov/25748293/	Sources: https://pubmed.ncbi.nlm.nih.gov/25748293/
6 mg 1 times / day multiple, oral Highest studied dose Dose: 6 mg, 1 times / day Route: oral Route: multiple Dose: 6 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17118761/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17118761/	Other AEs: Osteonecrosis of jaw... Other AEs: Osteonecrosis of jaw Sources: https://pubmed.ncbi.nlm.nih.gov/17118761/

AEs

AE	Significance	Dose	Population
Acute kidney injury		56 mg single, oral Higher than recommended Dose: 56 mg Route: oral Route: single Dose: 56 mg Sources: https://pubmed.ncbi.nlm.nih.gov/23774552/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/23774552/
Osteonecrosis of jaw		6 mg 1 times / day multiple, oral Highest studied dose Dose: 6 mg, 1 times / day Route: oral Route: multiple Dose: 6 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17118761/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17118761/

PubMed

Title	Date	PubMed
Reduction of metastasis, cell invasion, and adhesion in mouse osteosarcoma by YM529/ONO-5920-induced blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathway.	2012-03-15	22326785
Expression of Msx-1 is suppressed in bisphosphonate associated osteonecrosis related jaw tissue-etiopathology considerations respecting jaw developmental biology-related unique features.	2010-10-13	20942943
Synthesis, chiral high performance liquid chromatographic resolution and enantiospecific activity of a potent new geranylgeranyl transferase inhibitor, 2-hydroxy-3-imidazo[1,2-a]pyridin-3-yl-2-phosphonopropionic acid.	2010-05-13	20394422
Anti-tumour activity of bisphosphonates in preclinical models of breast cancer.	2010	21176176
[New development in bisphosphonate treatment. Review of the preventive effect of minodronic acid on fracture in Japanese patients with osteoporosis].	2009-01	19122267
[New development in bisphosphonate treatment. Review of effect on bone metabolism by minodronic acid in primary osteoporosis].	2009-01	19122266
Minodronic acid (ONO-5920/YM529) prevents decrease in bone mineral density and bone strength, and improves bone microarchitecture in ovariectomized cynomolgus monkeys.	2008-11	18718565
Long-term minodronic acid (ONO-5920/YM529) treatment suppresses increased bone turnover, plus prevents reduction in bone mass and bone strength in ovariectomized rats with established osteopenia.	2008-11	18687415
Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation.	2008-09-25	18800762
Minodronic acid, a third-generation bisphosphonate, antagonizes purinergic P2X(2/3) receptor function and exerts an analgesic effect in pain models.	2008-07-28	18565509
Efficacy of a nitrogen-containing bisphosphonate, minodronate, in conjunction with a p38 mitogen activated protein kinase inhibitor or doxorubicin against malignant bone tumor cells.	2008-06	17874104
[New bone density conservation agents for osteoporosis under research and development: Minodronic acid].	2007-11-28	18161142
Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma.	2007-01-29	17242698
Anti-tumor effect of bisphosphonate (YM529) on non-small cell lung cancer cell lines.	2007-01-12	17222343
Minodronic acid influences receptor activator of nuclear factor kappaB ligand expression and suppresses bone resorption by osteoclasts in rats with collagen-induced arthritis.	2007	17564774
A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo.	2006-11-20	17043684
The effect of bisphosphonates on gene expression: GAPDH as a housekeeping or a new target gene?	2006-03-03	16515701
Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2.	2005-03-04	15670755
A third-generation bisphosphonate, minodronic acid (YM529), augments the interferon alpha/beta-mediated inhibition of renal cell cancer cell growth both in vitro and in vivo.	2005-01-15	15701876
Effects of YM529, a novel minodronic acid, on adjuvant arthritis in rats.	2004-03-10	15005007
Effect of minodronic acid (ONO-5920) on bone mineral density and arthritis in adult rats with collagen-induced arthritis.	2003-06	12794842
A new stressed test to predict the foreign matter formation of minodronic acid in solution.	2003-01-30	12527179
Failure of stability prediction for minodronic acid injectable by accelerated stability testing.	2002-07-08	12086722
Stabilization of minodronic acid in aqueous solution for parenteral formulation.	2001-07-03	11404035
Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.	2001-02	11160603

Patents

Sample Use Guides

In Vivo Use Guide

Normally in adults, 1 mg of minodronic acid (RECALBON®, Bonoteo®) is taken orally together with enough amount of water (180 ml) (or lukewarm water) once a day at the time of awakening. The drug must be taken without lying down at least for 30 minutes before the first food, beverage (other than plain water), and other oral medication.

Route of Administration: Oral

In Vitro Use Guide

The bone-binding characteristics of minodronic acid and morphological changes in rabbit osteoclasts were analyzed in vitro. In an osteoclast culture with 1 uM minodronic acid, 65% of minodronic acid was bound to bone, and C-terminal cross-linking telopeptide release was inhibited by 96%. Cultured osteoclasts without minodronic acid treatment formed ruffled borders and bone resorption lacunae and had rich cytoplasm, whereas those treated with 1 uM minodronic acid were not multinucleated, stained densely with toluidine blue, and were detached from the bone surface.

Substance Class	Chemical Created by `admin` on `Wed Apr 02 07:02:28 GMT 2025` Edited by `admin` on `Wed Apr 02 07:02:28 GMT 2025`
Record UNII	40SGR63TGL
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MINODRONIC ACID

Official Name

English

ONO-5920

Preferred Name

English

MINODRONIC ACID [MI]

Common Name

English

MINODRONIC ACID [MART.]

Common Name

English

minodronic acid [INN]

Common Name

English

PHOSPHONIC ACID, (1-HYDROXY-2-IMIDAZO(1,2-A)PYRIDIN-3-YLETHYLIDENE)BIS-

Common Name

English

YM529

Code

English

Minodronic acid [WHO-DD]

Common Name

English

YM-529

Code

English

NSC-725590

Code

English

MINODRONATE

Common Name

English

(1-HYDROXY-2-IMIDAZO(1,2-A)PYRIDIN-3-YLETHYLIDENE)DIPHOSPHONIC ACID

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C67439